Altimmune, Inc. (ALT) Form 10-Q — May 13, 2026
Altimmune, Inc. reported a net loss of $22.6 million for the quarter ended March 31, 2026, compared to a net loss of $19.6 million for the same period in 2025. The increase in net loss is primarily due to higher general and administrative expenses, including severance costs for a former executive officer. The company's cash and cash equivalents as of March 31, 2026, were $97.6 million, up from $43.8 million as of December 31, 2025.
Key figures
- Net Loss
- 22563
- Revenue
- 0
- Total Debt
- 34505
- Total Assets
- 335630
- Cash Position
- 97643
- Shares Outstanding
- 130221154
Price after filing
1 day: -3.3%7 days: -6.6%30 days: -14.2%
Close on the filing date to close N calendar days later (from $3.02). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.